Why Investors Are Voting Against VIVUS
In this video, health-care analyst David Williamson discusses the sector's three biggest losers today, including VIVUS after posting poor third-quarter results. Watch and find out what investors should take away from these disappointing results and catch up on the day's other big movers.
The ravages of America's obesity epidemic pose a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand-new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.
The article Why Investors Are Voting Against VIVUS originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. David Williamson and The Motley Fool own shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.